Sesterhenn Ia, Weiss Rb. Mostofi FK, et al Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma. Clin Oncol. 1992;69–78.
2.
Fung C, La K, Brodsky G. et al stage I nonseminomatous germ cell testicular tumor: prediction of metastatic potential by primary histopathology. Clin Oncol. 1998;1467–73.
3.
Jewett M. alison rE, et al surveillance after orchiectomy for patients with stage I nonseminomatous testis tumors. j Clin Oncol. 1992;564–8.
4.
Ls F, Parkinson M, Jones W. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet. 1987;294–8.
5.
Klepp O, Olsson Am, Henrikson H. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. j Clin Oncol. 1990;509–18.
Stevens Mj, Norman Ar, Fisher C. Prognosis of testicular teratoma differentiated. Br j Urol. 1994;701–6.
8.
Simmonds Pd L, Ahs. Theaker jM, et al Primary pure teratoma of the testis. j Urol. 11996;939–42.
9.
Read G, Cullen M. Medical research Council prospective study of surveillance for stage I testicular teratoma. j Clin Oncol. 1992;1762–8.
10.
Abell Mr, Holz F. Testicular neoplasms in infant and children: I. Tumors of germ cell origin. Cancer. 1963;965–71.
11.
Leibovitch I, Foster Rs, Ulbright T. Cancer. 1995;2244–50.
12.
Rabbani F, Farivar-Mohseni H, Leon. Clinical outcome after retroperitoneal lymphadenectomy of patients with pure testicular teratoma. Urology. 2003;(6):1092–6.
13.
Heidenreich A, Moul Jw, Mcleod Dg. The role of retroperitoneal lymphadenectomy in mature teratoma of the testis. j Urol. 1997;160–3.
14.
Herr H. Urol Clin North am. 1993;145–52.
15.
Foster Rs, Baniel J, Leibovitch I. Teratoma in the orchiectomy specimen and volume of metastasis are predictors of retroperitoneal teratoma in low stage nonseminomatous testis cancer. Urol. 1996;1943–5.
16.
Motzer F. Incidence and clinical outcome of patients with teratoma in the retroperitoneum following primary rPLNd for clinical stage I and IIa NsGCT. j Urol. 2001;153.
17.
argirovic d, argirovic a, stanic V Long term outcome after postchemotherapy retroperitoneal lymphadenectomy in patients with pure teratoma. Eur Urol. 2010;(2):236.
18.
Predicting teratoma in the retroperitoneum in men undergoing post-chemotherapy retroperitoneal lymphadenectomy. Eur Urol. 2010;(6):573.
19.
Baniel J F, Rs. Gonin r, et al Late relapse of testicular cancer. Clin Oncol. 1995;1170–6.
20.
Late relapses following treatment for nonseminomatous testicular tumors according to single centerbased experience. Eur Urol. 2007;(2):157.
21.
Late relapses of germ cell testicular tumors following cisplatin-based chemotherapy. Eur Urol Meet. 2007;(7).
22.
Motzer, Pieto V. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. Urol. 1998;133–8.
23.
Cj L. Trinidade a, et al The growing teratoma syndrome. Cancer. 1982;1629–35.
24.
argirovic d retroperitoneal lymphadenectomy or primary cisplatin-based chemotherapy in clinical stage B1/B2 nonseminomatous testicular tumors: Long term results of the prospective non-randomized study. Eur Urol Meet. 2007;(7):137.
25.
Rabbani F, Gleave M, Copin C. Teratoma in primary testis tumor reduces complete response rate in the retroperitoneum after primary chemotherapy: case for primary retroperitoneal node dissection in stage IIB germ cell tumors with teratomatous elements. Cancer. 1996;480–6.
26.
Steyerberg E, Hj K, Fossa Sd. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumor: multivariate analysis of individual patient data from six study group. Clin Oncol. 1995;1177–87.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
